Literature DB >> 27772783

Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.

Joachim G Schulz1, Bernard Kreps2.   

Abstract

Entities:  

Keywords:  Anticoagulation; Idarucizumab; Stroke; Thrombolysis

Mesh：

Substances：

Year:  2016        PMID： 27772783     DOI： 10.1016/j.jns.2016.09.010

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN： 0022-510X            Impact factor:   3.181


× No keyword cloud information.
  8 in total

1.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

2.  Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis.

Authors:  Felix C Ng; James Bice; Anne Rodda; Matthew Lee-Archer; Douglas E Crompton
Journal:  J Neurol       Date:  2017-02-06       Impact factor: 4.849

3.  Anticoagulants: Updates on idarucizumab.

Authors:  J S Chandan; T Thomas; H S Baryah
Journal:  Br Dent J       Date:  2017-02-10       Impact factor: 1.626

4.  Thrombolysis in Acute Ischemic Stroke after Idarucizumab for Dabigatran Etexilate Reversal in Elderly: A Case Report.

Authors:  Antonio Baule; Federico Cabigiosu; Bastianina Zanda; Alessandra Sanna; Claudia Mongili; Antonio Manca
Journal:  J Vasc Interv Neurol       Date:  2018-11

5.  Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.

Authors:  Sergio Agosti; Laura Casalino; Enrico Rocci; Gabriele Zaccone; Eugenia Rota
Journal:  J Med Case Rep       Date:  2017-08-15

Review 6.  Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence.

Authors:  Slaven Pikija; Laszlo K Sztriha; J Sebastian Mutzenbach; Stefan M Golaszewski; Johann Sellner
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

7.  Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature.

Authors:  Senta Frol; Dimitrios Sagris; Janja Pretnar Oblak; Mišo Šabovič; George Ntaios
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

8.  Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations.

Authors:  Kazunori Toyoda; Hiroshi Yamagami; Masatoshi Koga
Journal:  J Stroke       Date:  2018-09-30       Impact factor: 6.967
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.